These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 35965494)

  • 1. Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation.
    Avery TY; Köhler N; Zeiser R; Brummer T; Ruess DA
    Front Oncol; 2022; 12():931774. PubMed ID: 35965494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationships among
    Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
    World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MEK inhibitors and DA-Raf, a dominant-negative antagonist of the Ras-ERK pathway, prevent the migration and invasion of KRAS-mutant cancer cells.
    Matsuda A; Masuzawa R; Takahashi K; Takano K; Endo T
    Cytoskeleton (Hoboken); 2024 Jun; ():. PubMed ID: 38872577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperactivation of MAPK Signaling Is Deleterious to RAS/RAF-mutant Melanoma.
    Leung GP; Feng T; Sigoillot FD; Geyer FC; Shirley MD; Ruddy DA; Rakiec DP; Freeman AK; Engelman JA; Jaskelioff M; Stuart DD
    Mol Cancer Res; 2019 Jan; 17(1):199-211. PubMed ID: 30201825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein kinase C alpha trigger Ras and Raf-independent MEK/ERK activation for TPA-induced growth inhibition of human hepatoma cell HepG2.
    Wen-Sheng W
    Cancer Lett; 2006 Jul; 239(1):27-35. PubMed ID: 16169661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting RAS-RAF-MEK-ERK signaling pathway in human cancer: Current status in clinical trials.
    Song Y; Bi Z; Liu Y; Qin F; Wei Y; Wei X
    Genes Dis; 2023 Jan; 10(1):76-88. PubMed ID: 37013062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Future targeting of the RAS/RAF/MEK/ERK signaling pathway in oncology: the example of melanoma].
    Favre G
    Bull Acad Natl Med; 2014 Feb; 198(2):321-36; discussion 337-8. PubMed ID: 26263707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational analysis of the RAS/RAF/MEK/ERK signaling pathway in 260 Han Chinese patients with cervical carcinoma.
    Zou Y; Liu FY; Wu J; Wan L; Fang SF; Zhang ZY; Luo Y; Chen MH; Huang MZ; He M; Huang OP
    Oncol Lett; 2017 Aug; 14(2):2427-2431. PubMed ID: 28781678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.
    Steelman LS; Franklin RA; Abrams SL; Chappell W; Kempf CR; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo P; Ruvolo V; Evangelisti C; Martelli AM; McCubrey JA
    Leukemia; 2011 Jul; 25(7):1080-94. PubMed ID: 21494257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation.
    Xu J; Pfarr N; Endris V; Mai EK; Md Hanafiah NH; Lehners N; Penzel R; Weichert W; Ho AD; Schirmacher P; Goldschmidt H; Andrulis M; Raab MS
    Oncogenesis; 2017 May; 6(5):e337. PubMed ID: 28504689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
    Nissan MH; Pratilas CA; Jones AM; Ramirez R; Won H; Liu C; Tiwari S; Kong L; Hanrahan AJ; Yao Z; Merghoub T; Ribas A; Chapman PB; Yaeger R; Taylor BS; Schultz N; Berger MF; Rosen N; Solit DB
    Cancer Res; 2014 Apr; 74(8):2340-50. PubMed ID: 24576830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MEK inhibitors for the treatment of non-small cell lung cancer.
    Han J; Liu Y; Yang S; Wu X; Li H; Wang Q
    J Hematol Oncol; 2021 Jan; 14(1):1. PubMed ID: 33402199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.
    Joseph EW; Pratilas CA; Poulikakos PI; Tadi M; Wang W; Taylor BS; Halilovic E; Persaud Y; Xing F; Viale A; Tsai J; Chapman PB; Bollag G; Solit DB; Rosen N
    Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14903-8. PubMed ID: 20668238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
    Wang AX; Qi XY
    IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation.
    Heard JJ; Phung I; Potes MI; Tamanoi F
    BMC Cancer; 2018 Jan; 18(1):69. PubMed ID: 29320991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
    Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
    Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathway crosstalk between Ras/Raf and PI3K in promotion of M-CSF-induced MEK/ERK-mediated osteoclast survival.
    Bradley EW; Ruan MM; Vrable A; Oursler MJ
    J Cell Biochem; 2008 Jul; 104(4):1439-51. PubMed ID: 18275061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K-RAS mutant tumors.
    Yuan X; Tang Z; Du R; Yao Z; Cheung SH; Zhang X; Wei J; Zhao Y; Du Y; Liu Y; Hu X; Gong W; Liu Y; Gao Y; Huang Z; Cao Z; Wei M; Zhou C; Wang L; Rosen N; Smith PD; Luo L
    Mol Oncol; 2020 Aug; 14(8):1833-1849. PubMed ID: 32336014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
    Saini KS; Loi S; de Azambuja E; Metzger-Filho O; Saini ML; Ignatiadis M; Dancey JE; Piccart-Gebhart MJ
    Cancer Treat Rev; 2013 Dec; 39(8):935-46. PubMed ID: 23643661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.
    Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD
    J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.